Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics posts October 2026 investor presentation on its website

Neutral Impact 1 of 5 other Written later

Ernexa Therapeutics Inc. made an investor presentation available on October 15, 2026, attached as Exhibit 99.1 and posted on its website. The filing is a Regulation FD disclosure and contains no financial results, guidance or deal terms in the text provided, so the filing itself gives shareholders no new financial figures.

Key points

  • Investor presentation made available October 15, 2026, attached as Exhibit 99.1 and posted at investor.ernexatx.com
  • Filing is furnished under Item 7.01 Regulation FD Disclosure, not filed for Section 18 purposes
  • Exhibit 99.1 is titled Ernexa Therapeutics Investor Presentation - October 2026; its contents are not included in the filing text provided

The filing

CompanyErnexa Therapeutics Inc. (ERNA)
Form8-K, current report
Filed with the SECOct 15, 2026, 5:25 PM ET
Accession number0001493152-26-047287

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.